inriver Showcases Innovations and Customer Success at PIMpoint Europe 2023
9.5.2023 09:00:00 EEST | Business Wire | Press release
inriver, the leading software company powering the entire product journey with revenue-driving product information management (PIM) across every customer touchpoint, today unveiled a significant new product innovation and showcased leading brand partners at PIMpoint Europe 2023, its annual conference and the world’s largest product information management event.
This year’s event is highlighted by inriver’s new breed of PIM, an evolution of traditional product information management solutions. As a result of this new breed of PIM, inriver announced continued product innovation to the inriver PIM platform, including ChatGPT functionality to create efficiencies for augmenting product data, and further showcased the power of its now-available syndication capabilities. These innovations have allowed inriver to deliver even more operational efficiency, built-in digital shelf analytics, expanded sales opportunities, and greater sustainability benefits.
“We face unprecedented demand for more sustainability from brands, retailers, and manufacturers as a result of our increasingly circular economy. PIMpoint Europe 2023 comes at such a pivotal moment for our community,” said Niels Stenfeldt, inriver CEO. “As the world prepares for the European Union’s new Digital Product Passport initiative, the new breed of PIM turns global demands for supply chain transparency into new growth drivers for manufacturing companies. There is no better time to welcome our peers across so many industries for meaningful conversations for the future.”
Joining inriver are customer and partner showcases led by leading brands such as Michelin, Victorinox, Öob, Fluidra and more. These brands represent world-class PIM users that inriver helps create, enrich, and syndicate product information across a variety of channels and marketplaces.
Another brand, and inriver customer appearing at PIMpoint is Lantmännen, Northern Europe’s leader in agriculture, machinery, bioenergy and food products. Owned by 18,000 Swedish farmers and with 10,000 employees, Lantmännen has operations in over 20 countries and an annual revenue of approximately SEK 60 billion.
“Lantmännen has a long-term approach to farming, taking an active role in creating more sustainable energy and food supply. We take responsibility from field to fork and focus on issues that are of importance for sustainable, profitable, and thriving farming,” said Håkan Jägbrink, Platform Manager for the IT Commercial Backbone at Lantmännen. “As we are building a sustainable value chain across multiple companies and industries, Lantmännen requires our product data to be complete and accurate. The inriver PIM solution allows us to connect the data across people, processes, and our metadata structure for our 7 different companies. The inriver PIM’s flexible, elastic data model powers our product journey to drive efficiencies and cost reductons. Further, inriver is developing in exactly the right direction for our upcoming requirements.”
In addition to product innovations, brand, and partner showcases, inriver also announced the recipients of the 2022 inriver awards. The awards highlight organizations and individuals leading the industry and driving change in digital commerce and product information management. PIMpoint Europe Award winners:
- 2022 Alliance Ambassador of the Year, Global — Salesforce
- 2022 Alliance Partner of the Year, Global — Bynder
- 2022 Customer of the Year, EMEA — Fluidra
- 2022 Customer Ambassador of the Year, EMEA — Christopher Klumpp, Victorinox
- 2022 Partner of the Year, EMEA — Nexer
- 2022 Partner Project of the Year, EMEA — Nexer for Lantmännen
- 2022 Community Ambassador of the Year, Global — Mark Stuart-Walker, Luceco plc
“This has been a truly awe-inspiring year for the PIM community and the recipients of the 2022 inriver awards are not only being recognized for industry-leading PIM use cases, projects, and innovation but for their dedication to collaboration and business transformation,” said Brooke Cunningham, Chief Marketing Officer, inriver. “This year’s winning customers are leading from the front with their product information strategies, and these partners are committed to helping our joint customers power their entire product journeys. On behalf of the inriver leadership team, I want to thank each and every award recipient for their contribution to driving successful business outcomes.”
PIMpoint is made possible by the inriver valued partner ecosystem and the role it plays in delivering impactful customer stories, including the PIMpoint 2023 Global sponsors Optimizely and Nexer, as well as Europe sponsors Bynder, Delaware, Digizuite, Lengoo, Transperfect, Aprimo, Diamir Consulting, FotoWare, Geta, Immeo, Tietoevry, Etac, Avensia, ChannelEngine, Cypoint Inspire AB, Mad Max Consulting, Priint, and Xsarus.
In addition to customer and partner momentum in the Nordics market, inriver continues to invest in leadership and talent to support its local workforce. Ulrica Falkenberg has recently been appointed as Chief People and Culture Officer for the company based in Stockholm. An accomplished executive and Swedish national, Falkenberg most recently served as CHRO at Trustly, a digital payments company, and has served as an executive at Alumni Harvey Nash, an Executive Talent firm, as well as Max Mara Fashion Group.
About inriver
inriver powers the entire product journey at every touchpoint. The inriver configurable PIM solution, with built-in digital shelf analytics and integration capabilities, connects to your digital ecosystem with flexibility and ease, so it grows as your company grows. With more demands on product data than ever before, B2B and B2C enterprises need a PIM solution that supports the entire product cycle, from sourcing to decommissioning and every stage in between.
inriver helps brands, manufacturers, and retailers turn product information into strategic assets, maximizing profitability at every touchpoint for 1,600+ global brands. Headquartered in Malmö, Sweden, and with offices worldwide, inriver has a team of over 375 people ready to strengthen your product journey. For more information, visit inriver.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230508005195/en/
Contact information
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 12:18:00 EEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
